XNYS
EW
Market cap52bUSD
Jul 09, Last price
91.33USD
1D
-2.47%
1Q
17.29%
Jan 2017
192.41%
IPO
6,724.18%
Name
Edwards Lifesciences Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Edwards Lifesciences, a global medical technology leader, specializes in developing advanced solutions for structural heart conditions and critical care/surgical monitoring. Operating across the U.S., Europe, Japan, and other international markets, the company provides transcatheter heart valve therapies for minimally invasive replacement and repair, specifically targeting mitral and tricuspid valve diseases. Its innovative offerings include the PASCAL and Cardioband transcatheter valve repair systems. Beyond transcatheter devices, Edwards Lifesciences manufactures a comprehensive range of surgical structural heart products, such as the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex replacements, and the HARPOON Beating Heart Mitral Valve Repair System for degenerative mitral regurgitation. The firm also delivers crucial critical care solutions, including sophisticated hemodynamic monitoring systems for assessing cardiac function and fluid balance in surgical and ICU settings, alongside the Acumen Hypotension Prediction Index software, which proactively warns clinicians about impending dangerously low blood pressure. Products are distributed via an in-house sales team and independent distributors. Established in 1958, Edwards Lifesciences Corporation is headquartered in Irvine, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||